Anti-il13rα2 antibodies and their use in anti-tumor chimeric antigen receptor t cells
By developing seven novel anti-IL13Rα2 antibodies and constructing CAR-T cells, the problem of limited efficacy of existing IL13Rα2 CAR-T therapy for glioblastoma has been solved, achieving highly efficient killing and specific targeting of IL13Rα2-positive tumor cells.
Patent Information
- Application Number
- CN202611530047.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-30
- Publication Date
- 2026-11-10
AI Technical Summary
Current IL13Rα2 CAR-T therapy for glioblastoma has limited efficacy, necessitating the development of more specific and potent antibody sequences to enhance treatment outcomes.
Seven novel anti-IL13Rα2 antibodies were provided, named antibodies CX3, CX4, CX5, CX8, CX9, CX10 and CX11, and corresponding chimeric antigen receptor T cells (CAR-T cells) were constructed. With their scFv sequences as the core, the killing effect on IL13Rα2 positive cells was significantly enhanced.
These antibodies exhibit significant specificity, effectively killing IL13Rα2-positive tumor cells without damaging IL13Rα2-negative cells, demonstrating significant potential for drug development targeting IL13Rα2-positive tumors.
Smart Images

Figure CN123062576A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biopharmaceutical technology, and in particular relates to anti-IL13Rα2 antibody and its application in anti-tumor chimeric antigen receptor T cells. Background Technology
[0002] Glioblastoma (GBM) is the most malignant primary tumor of the adult central nervous system, characterized by diffuse invasive growth, significant spatiotemporal heterogeneity, a strongly immunosuppressive microenvironment, and the natural barrier function of the blood-brain barrier. Current standard treatment primarily involves maximal surgical resection combined with concurrent chemoradiotherapy and temozolomide adjuvant chemotherapy. However, this approach struggles to completely eliminate small tumor lesions that have invaded normal brain tissue. The vast majority of patients experience tumor recurrence within a short period, with a median survival of less than 15 months and an overall extremely poor prognosis. Therefore, there is an urgent clinical need to develop novel targeted immunotherapies.
[0003] Chimeric antigen receptor T-cell (CAR-T) immunotherapy utilizes genetic engineering to modify autologous or allogeneic T lymphocytes, freeing them from MHC molecular restrictions. This allows them to specifically recognize tumor surface antigens and initiate direct killing pathways, achieving a landmark breakthrough in hematologic malignancies and opening new avenues for the treatment of solid tumors, especially central nervous system tumors. CAR-T cells targeting IL13Rα2 have demonstrated potent specific anti-tumor activity in numerous in vitro experiments and orthotopic animal models of gliomas. In recent years, clinical translational research on IL13Rα2 CAR-T has continued to advance, with results from several Phase I clinical trials being published. A large-scale Phase I clinical study published in Nature Medicine in 2024 demonstrated good safety profiles for intratumoral injection, intraventricular infusion, and combined local administration routes. Objective tumor remission cases were observed in patients with recurrent high-grade gliomas, confirming that local administration, compared to intravenous infusion, effectively circumvents the blood-brain barrier and increases the enrichment level of CAR-T cells in cerebrospinal fluid and tumor lesions. Meanwhile, new generation modification strategies are constantly emerging, including bispecific CARs (IL13Rα2 / B7H3, IL13Rα2 / EGFR), cytokine-armored CAR-T, and enriched central memory T cell preparation processes; universal allogeneic IL13Rα2 CAR-T (UCAR-T) uses CRISPR to knock out TRAC and HLA genes to reduce graft-versus-host disease. Preliminary Phase I data showed that patients with recurrent glioma achieved a high tumor remission rate, providing a new approach for patients who have difficulty preparing autologous CAR-T.
[0004] Despite the aforementioned progress, current IL13Rα2 CAR-T therapy still faces multiple core bottlenecks limiting its efficacy. Current research focuses on optimizing the intracellular signaling domain of CARs, combining with immune checkpoint inhibitors, oncolytic viruses, metabolic modulatory drugs, and innovative delivery strategies. However, most current research uses the natural ligand IL13 or the modified IL13-E13Y as the extracellular antigen recognition domain for CARs. Developing antibody sequences targeting IL13Rα2 with better specificity and stronger killing effects would help further improve the therapeutic effect of anti-IL13Rα2 CAR-T therapy, and has significant scientific value and clinical translational significance for improving the survival expectation of patients with recurrent gliomas. Summary of the Invention
[0005] To address the aforementioned technical problems, this invention provides an anti-IL13Rα2 antibody and its application in anti-tumor chimeric antigen receptor T cells.
[0006] The technical solution adopted in this invention is: anti-IL13Rα2 antibody, named antibody CX3, antibody CX4, antibody CX5, antibody CX8, antibody CX9, antibody CX10 or antibody CX11;
[0007] The variable region of the antibody CX3 light chain includes LCDR1 as shown in SEQ ID No. 1, LCDR2 as shown in SEQ ID No. 2, and LCDR3 as shown in SEQ ID No. 3; the variable region of the heavy chain includes HCDR1 as shown in SEQ ID No. 4, HCDR2 as shown in SEQ ID No. 5, and HCDR3 as shown in SEQ ID No. 6.
[0008] The variable region of the antibody CX4 light chain includes LCDR1 as shown in SEQ ID No. 11, LCDR2 as shown in SEQ ID No. 12, and LCDR3 as shown in SEQ ID No. 13; the variable region of the heavy chain includes HCDR1 as shown in SEQ ID No. 14, HCDR2 as shown in SEQ ID No. 15, and HCDR3 as shown in SEQ ID No. 16.
[0009] The variable region of the antibody CX5 light chain includes LCDR1 as shown in SEQ ID No. 21, LCDR2 as shown in SEQ ID No. 22, and LCDR3 as shown in SEQ ID No. 23; the variable region of the heavy chain includes HCDR1 as shown in SEQ ID No. 24, HCDR2 as shown in SEQ ID No. 25, and HCDR3 as shown in SEQ ID No. 26.
[0010] The variable region of the antibody CX8 light chain includes LCDR1 as shown in SEQ ID No. 31, LCDR2 as shown in SEQ ID No. 32, and LCDR3 as shown in SEQ ID No. 33; the variable region of the heavy chain includes HCDR1 as shown in SEQ ID No. 34, HCDR2 as shown in SEQ ID No. 35, and HCDR3 as shown in SEQ ID No. 36.
[0011] The variable region of the antibody CX9 light chain includes LCDR1 as shown in SEQ ID No. 41, LCDR2 as shown in SEQ ID No. 42, and LCDR3 as shown in SEQ ID No. 43; the variable region of the heavy chain includes HCDR1 as shown in SEQ ID No. 44, HCDR2 as shown in SEQ ID No. 45, and HCDR3 as shown in SEQ ID No. 46.
[0012] The variable region of the light chain of antibody CX10 includes LCDR1 with the sequence shown in SEQ ID No. 51, LCDR2 with the sequence shown in SEQ ID No. 52, and LCDR3 with the sequence shown in SEQ ID No. 53; the variable region of the heavy chain includes HCDR1 with the sequence shown in SEQ ID No. 54, HCDR2 with the sequence shown in SEQ ID No. 55, and HCDR3 with the sequence shown in SEQ ID No. 56.
[0013] The variable region of the light chain of antibody CX11 includes LCDR1 with the sequence shown in SEQ ID No. 61, LCDR2 with the sequence shown in SEQ ID No. 62, and LCDR3 with the sequence shown in SEQ ID No. 63; the variable region of the heavy chain includes HCDR1 with the sequence shown in SEQ ID No. 64, HCDR2 with the sequence shown in SEQ ID No. 65, and HCDR3 with the sequence shown in SEQ ID No. 66.
[0014] Preferably, the amino acid sequence of the variable region of the light chain of antibody CX3 is shown in SEQ ID No. 7, and the amino acid sequence of the variable region of the heavy chain is shown in SEQ ID No. 9;
[0015] The amino acid sequence of the light chain variable region of antibody CX4 is shown in SEQ ID No. 17, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 19.
[0016] The amino acid sequence of the light chain variable region of antibody CX5 is shown in SEQ ID No. 27, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 29.
[0017] The amino acid sequence of the light chain variable region of antibody CX8 is shown in SEQ ID No. 37, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 39.
[0018] The amino acid sequence of the light chain variable region of antibody CX9 is shown in SEQ ID No. 47, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 49.
[0019] The amino acid sequence of the light chain variable region of antibody CX10 is shown in SEQ ID No. 57, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 59.
[0020] The amino acid sequence of the light chain variable region of antibody CX11 is shown in SEQ ID No. 67, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 69.
[0021] Preferably, the nucleotide sequence encoding the variable region of the light chain of antibody CX3 is shown in SEQ ID No. 8, and the nucleotide sequence encoding the variable region of the heavy chain is shown in SEQ ID No. 10;
[0022] The nucleotide sequence encoding the light chain variable region of antibody CX4 is shown in SEQ ID No. 18, and the nucleotide sequence encoding the heavy chain variable region is shown in SEQ ID No. 20.
[0023] The nucleotide sequence encoding the light chain variable region of antibody CX5 is shown in SEQ ID No. 28, and the nucleotide sequence encoding the heavy chain variable region is shown in SEQ ID No. 30.
[0024] The nucleotide sequence encoding the variable region of the light chain of antibody CX8 is shown in SEQ ID No. 38, and the nucleotide sequence encoding the variable region of the heavy chain is shown in SEQ ID No. 40.
[0025] The nucleotide sequence encoding the light chain variable region of antibody CX9 is shown in SEQ ID No. 48, and the nucleotide sequence encoding the heavy chain variable region is shown in SEQ ID No. 50.
[0026] The nucleotide sequence encoding the light chain variable region of antibody CX10 is shown in SEQ ID No. 58, and the nucleotide sequence encoding the heavy chain variable region is shown in SEQ ID No. 60.
[0027] The nucleotide sequence encoding the light chain variable region of antibody CX11 is shown in SEQ ID No. 68, and the nucleotide sequence encoding the heavy chain variable region is shown in SEQ ID No. 70.
[0028] A chimeric antigen receptor T cell comprising an expression vector containing an scFv sequence of an anti-IL13Rα2 antibody, named CAR-T-CX3, CAR-T-CX4, CAR-T-CX5, CAR-T-CX8, CAR-T-CX9, CAR-T-CX10 or CAR-T-CX11.
[0029] Preferably, the expression vector includes the scFv sequence of antibody CX4 or CX10.
[0030] Application of chimeric antigen receptor T cells in the preparation of antitumor drugs.
[0031] Preferably, it is used for IL13Rα2-positive tumor cells.
[0032] Preferably, it is a drug for glioblastoma.
[0033] The advantages and positive effects of this invention are: it provides seven novel anti-IL13Rα2 antibodies, and the chimeric antigen receptor T cells constructed with their scFv sequences as the core have a better killing effect on IL13Rα2 positive cells and no loss of IL13Rα2 negative cells, and have significant specificity; it can be used in the development of drugs targeting IL13Rα2 positive tumors. Attached Figure Description
[0034] Figure 1 CAR structure diagram;
[0035] Figure 2 Flow cytometry analysis of CAR-T positivity rate;
[0036] Figure 3 The killing effect of different CAR-T cells on human glioma cell line U87;
[0037] Figure 4 The killing effects of different CAR-T cells on U251 cells;
[0038] Figure 5 The killing effects of different CAR-T cells on A549 cells;
[0039] Figure 6 IL2 expression of CAR-T cells after co-incubation with U87 cells or U251 cells, respectively;
[0040] Figure 7IFN-γ expression after CAR-T cells were co-incubated with U87 cells or U251 cells, respectively. Detailed Implementation
[0041] The embodiments of the present invention will now be described with reference to the accompanying drawings.
[0042] This invention relates to anti-IL13Rα2 antibodies and their application in anti-tumor chimeric antigen receptor T cells. Seven anti-IL13Rα2 antibodies are provided, named CX3, CX4, CX5, CX8, CX9, CX10, and CX11. Chimeric antigen receptor T cells (CAR-T cells) were constructed using the scFv sequences of these seven antibodies as the core. Verification showed that each CAR-T cell exhibited significant killing activity against IL13Rα2-positive cells, and can be used for the development of anti-tumor drugs.
[0043] The light chain variable region of antibody CX3 includes LCDR1, LCDR2, and LCDR3. The sequence of LCDR1 is shown in SEQ ID No. 1, the sequence of LCDR2 is shown in SEQ ID No. 2, and the sequence of LCDR3 is shown in SEQ ID No. 3. It also includes frame region sequences outside the complementarity-determining regions. The heavy chain variable region includes HCDR1, HCDR2, and HCDR3. The sequence of HCDR1 is shown in SEQ ID No. 4, the sequence of HCDR2 is shown in SEQ ID No. 5, and the sequence of HCDR3 is shown in SEQ ID No. 6. It also includes frame region sequences outside the complementarity-determining regions. The amino acid sequence of the light chain variable region of antibody CX3 is shown in SEQ ID No. 7; it can be obtained by translating and expressing the nucleotide sequence shown in SEQ ID No. 8, or by translating and expressing a similar codon-optimized nucleotide sequence. The amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 9; it can be obtained by translating and expressing the nucleotide sequence shown in SEQ ID No. 10, or by translating and expressing a similar codon-optimized nucleotide sequence.
[0044] SEQ ID No. 1: QSLLHRNGYNY
[0045] SEQ ID No. 2: LGS
[0046] SEQ ID No. 3: MQALQTPYT
[0047] SEQ ID No. 4: GFTFSNAW
[0048] SEQ ID No. 5: IKSKSDGGTT
[0049] SEQ ID No.6:TIIGD
[0050] SEQ ID No.7:
[0051] DIVMTQSPLSLPVTPGEPASISCRSSQSLLHRNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKVEIK
[0052] SEQ ID No.8:
[0053] GATATTGTGATGACACAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTTCATAGAAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCCGTACACTTTTGGCCAGGGGACCAAGGTGGAGATCAAA
[0054] SEQ ID No.9:
[0055] EVQLVESGGGLVKPGGSHRLSCEASGFTFSNAWLNWVRQAPGQGLEWVGRIKSKSDGGTTEYAATVKGRFTISRDDSKNTLYLQMDSLKIEDTGVYFCTIIGDWGQGTLVTVSS
[0056] SEQ ID No.10:
[0057] GAGGTGCAACTGGTGGAGTCTGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCATAGACTCTCCTGTGAAGCCTCTGGATTCACTTTCAGTAACGCCTGGCTGAATTGGGTCCGCCAGGCTCCAGGGCAGGGGCTGGAGTGGGTTGGCCGTATTAAAAGCAAAAGTGATGGT GGGACAACAGAATACGCTGCAACCGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCGAAAAACACGCTGTATCTACAAATGGACAGCCTGAAAATCGAGGACACAGGCGTCTATTTCTGTACGATTATTGGGGACTGGGGCCAGGGAACACTGGTCACTGTCTCCTCA
[0058] The light chain variable region of antibody CX4 includes LCDR1, LCDR2, and LCDR3, with the LCDR1 sequence shown in SEQ ID No. 11, the LCDR2 sequence shown in SEQ ID No. 12, and the LCDR3 sequence shown in SEQ ID No. 13. It also includes frame region sequences outside the complementarity-determining regions. The heavy chain variable region includes HCDR1, HCDR2, and HCDR3, with the HCDR1 sequence shown in SEQ ID No. 14, the HCDR2 sequence shown in SEQ ID No. 15, and the HCDR3 sequence shown in SEQ ID No. 16. It also includes frame region sequences outside the complementarity-determining regions. The amino acid sequence of the light chain variable region of antibody CX4 is shown in SEQ ID No. 17; it can be obtained by translating and expressing the nucleotide sequence shown in SEQ ID No. 18, or by translating and expressing a similar codon-optimized nucleotide sequence. The amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 19; it can be obtained by translating and expressing the nucleotide sequence shown in SEQ ID No. 20, or by translating and expressing a similar codon-optimized nucleotide sequence.
[0059] SEQ ID No. 11: ESIGSF
[0060] SEQ ID No. 12: AAS
[0061] SEQ ID No. 13: QQANSFPFT
[0062] SEQ ID No. 14: GYTFTSYA
[0063] SEQ ID No.15:INAGNGNT
[0064] SEQ ID No.16:ARDLRERRDGAMDV
[0065] SEQ ID No.17:
[0066] DIRLTQSPSSLSASVGHRVTITCRASESIGSFLNWYQQKPGKAPNLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPFTFGPGTKVDIK
[0067] SEQ ID No.18:
[0068] GACATCCGGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGACACAGAGTCACCATCACTTGCCGGGCAAGTGAGAGCATTGGCAGCTTTTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAACCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCAACAGGCTAACAGTTTCCCCTTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAA
[0069] SEQ ID No.19:
[0070] EVHLVESGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARDLRERRDGAMDVWGQGTTVTVSS
[0071] SEQ ID No.20:
[0072] GAGGTGCATCTGGTGGAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGGTGCGCCAGGCCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAAATATT CACAGAAGTTCCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGAGAGATCTTCGGGAACGGCGAGATGGGGCAATGGACGTCTGGGGCCAAGGGACCACGGTCACTGTCTCCTCA
[0073] The light chain variable region of antibody CX5 includes LCDR1, LCDR2, and LCDR3. The sequence of LCDR1 is shown in SEQ ID No. 21, the sequence of LCDR2 is shown in SEQ ID No. 22, and the sequence of LCDR3 is shown in SEQ ID No. 23. It also includes frame region sequences outside the complementarity-determining regions. The heavy chain variable region includes HCDR1, HCDR2, and HCDR3. The sequence of HCDR1 is shown in SEQ ID No. 24, the sequence of HCDR2 is shown in SEQ ID No. 25, and the sequence of HCDR3 is shown in SEQ ID No. 26. It also includes frame region sequences outside the complementarity-determining regions. The amino acid sequence of the light chain variable region of antibody CX5 is shown in SEQ ID No. 27; it can be obtained by translation and expression of the nucleotide sequence shown in SEQ ID No. 28, or by translation and expression of a similar codon-optimized nucleotide sequence. The amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 29; it can be obtained by translation and expression of the nucleotide sequence shown in SEQ ID No. 30, or by translation and expression of a similar codon-optimized nucleotide sequence.
[0074] SEQ ID No. 21: QSLLHSNGYNY
[0075] SEQ ID No. 22: LGS
[0076] SEQ ID No. 23: MQALQTPYT
[0077] SEQ ID No. 24: GFTFSNAW
[0078] SEQ ID No.25:IKSKTDGGTT
[0079] SEQ ID No.26:TTVGY
[0080] SEQ ID No.27:
[0081] DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYFDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKVEIK
[0082] SEQ ID No.28:
[0083] GATGTTGTGATGACACAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTCCATAGTAATGGATACAACTATTTTGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCCGTACACTTTTGGCCAGGGGACCAAGGTGGAGATCAAA
[0084] SEQ ID No.29:
[0085] QVQLVQSGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTVGYWGQGTLVTVSS
[0086] SEQ ID No.30:
[0087] CAGGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTTAGACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAACGCCTGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCGTATTAAAAGCAAAACTGATGGT GGGACAACAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCAAAAAACACGCTGTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTACCACCGTGGGCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA
[0088] The light chain variable region of antibody CX8 includes LCDR1, LCDR2, and LCDR3. The sequence of LCDR1 is shown in SEQ ID No. 31, the sequence of LCDR2 is shown in SEQ ID No. 32, and the sequence of LCDR3 is shown in SEQ ID No. 33. It also includes frame region sequences outside the complementarity-determining regions. The heavy chain variable region includes HCDR1, HCDR2, and HCDR3. The sequence of HCDR1 is shown in SEQ ID No. 34, the sequence of HCDR2 is shown in SEQ ID No. 35, and the sequence of HCDR3 is shown in SEQ ID No. 36. It also includes frame region sequences outside the complementarity-determining regions. The amino acid sequence of the light chain variable region of antibody CX8 is shown in SEQ ID No. 37; it can be obtained by translating and expressing the nucleotide sequence shown in SEQ ID No. 38, or by translating and expressing a similar codon-optimized nucleotide sequence. The amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 39; it can be obtained by translating and expressing the nucleotide sequence shown in SEQ ID No. 40, or by translating and expressing a similar codon-optimized nucleotide sequence.
[0089] SEQ ID No. 31: QSLLHSNGYNY
[0090] SEQ ID No. 32: LGS
[0091] SEQ ID No. 33: MQALQTPYT
[0092] SEQ ID No. 34: GFTFRNAW
[0093] SEQ ID No.35:IRSKTDGETT
[0094] SEQ ID No.36:TTVGG
[0095] SEQ ID No.37:
[0096] DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKVEIK
[0097] SEQ ID No.38:
[0098] GATGTTGTGATGACACAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCCGTACACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA
[0099] SEQ ID No.39:
[0100] QLQLQESGGGLVKPGGSLRLSCAASGFTFRNAWMSWVRQAPGQGLEWVGRIRSKTDGETTEYVEPVKGRFTISRDDSKNTLYLQMNSLEIEDTAVYYCTTVGGWGQGTLVTVSS
[0101] SEQ ID No.40:
[0102] CAGCTGCAGCTGCAGGAGTCGGGGGGAGGCCTGGTAAAGCCGGGGGGGTCCCTTAGACTCTCCTGTGCAGCCTCTGGATTTACTTTCCGTAACGCCTGGATGAGCTGGGTCCGCCAGGCTCCAGGGCAGGGGCTGGAGTGGGTTGGCCGGATTAGAAGCAAAACTGATGGT GAGACAACAGAGTATGTTGAACCCGTGAAAGGCAGATTCACCATCTCAAGAGATGACTCAAAAAACACGCTGTATTTGCAAATGAACAGCCTGGAAATCGAAGACACAGCCGTATACTGTACCACAGTTGGGGGCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA
[0103] The light chain variable region of antibody CX9 includes LCDR1, LCDR2, and LCDR3. The sequence of LCDR1 is shown in SEQ ID No. 41, the sequence of LCDR2 is shown in SEQ ID No. 42, and the sequence of LCDR3 is shown in SEQ ID No. 43. It also includes frame region sequences outside the complementarity-determining regions. The heavy chain variable region includes HCDR1, HCDR2, and HCDR3. The sequence of HCDR1 is shown in SEQ ID No. 44, the sequence of HCDR2 is shown in SEQ ID No. 45, and the sequence of HCDR3 is shown in SEQ ID No. 46. It also includes frame region sequences outside the complementarity-determining regions. The amino acid sequence of the light chain variable region of antibody CX9 is shown in SEQ ID No. 47; it can be obtained by translation and expression of the nucleotide sequence shown in SEQ ID No. 48, or by translation and expression of a similar codon-optimized nucleotide sequence. The amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 49; it can be obtained by translation and expression of the nucleotide sequence shown in SEQ ID No. 50, or by translation and expression of a similar codon-optimized nucleotide sequence.
[0104] SEQ ID No. 41: QSLLHSNGYNY
[0105] SEQ ID No. 42: LGS
[0106] SEQ ID No. 43: MQALQTPYT
[0107] SEQ ID No. 44: GFTFSNAW
[0108] SEQ ID No.45:IRSKTDGETT
[0109] SEQ ID No.46:TTVGG
[0110] SEQ ID No.47:
[0111] DVVMTQTPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKVEIK
[0112] SEQ ID No.48:
[0113] GATGTTGTGATGACTCAGACTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCCGTACACTTTTGGCCAGGGGACCAAGGTGGAAATCAAA
[0114] SEQ ID No.49:
[0115] QVQLVQSGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGQGLEWVGRIRSKTDGETTEYVEPVKGRFTISRDDSKNTLYLQMNSLEIEDTAVYYCTTVGGWGQGTLVTVSS
[0116] SEQ ID No.50:
[0117] CAGGTCCAGCTGGTACAGTCTGGGGGAGGCTTGGTAAAACCTGGCGGGTCCCTTAGACTCTCCTGTGCGGCCTCTGGATTCACTTTCAGTAACGCCTGGATGAGCTGGGTCCGCCAGGCTCCAGGGCAGGGGCTGGAGTGGGTTGGCCGGATTAGAAGCAAAACTGATGGT GAGACAACAGAGTATGTTGAACCCGTGAAAGGCAGATTCACCATCTCAAGAGATGACTCAAAAAACACGCTGTATTTGCAAATGAACAGCCTGGAAATCGAAGACACAGCCGTATACTGTACCACAGTTGGGGGCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA
[0118] The light chain variable region of antibody CX10 includes LCDR1, LCDR2, and LCDR3, with the LCDR1 sequence shown in SEQ ID No. 51, the LCDR2 sequence shown in SEQ ID No. 52, and the LCDR3 sequence shown in SEQ ID No. 53. It also includes frame region sequences outside the complementarity-determining regions. The heavy chain variable region includes HCDR1, HCDR2, and HCDR3, with the HCDR1 sequence shown in SEQ ID No. 54, the HCDR2 sequence shown in SEQ ID No. 55, and the HCDR3 sequence shown in SEQ ID No. 56. It also includes frame region sequences outside the complementarity-determining regions. The amino acid sequence of the light chain variable region of antibody CX10 is shown in SEQ ID No. 57; it can be obtained by translating and expressing the nucleotide sequence shown in SEQ ID No. 58, or by translating and expressing a similar codon-optimized nucleotide sequence. The amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 59; it can be obtained by translating and expressing the nucleotide sequence shown in SEQ ID No. 60, or by translating and expressing a similar codon-optimized nucleotide sequence.
[0119] SEQ ID No. 51: QGISSW
[0120] SEQ ID No. 52: AAS
[0121] SEQ ID No. 53: QQANSFPYT
[0122] SEQ ID No. 54: GYTFTSY
[0123] SEQ ID No.55:INAGNGNT
[0124] SEQ ID No.56:ARDLRERRDGAMDV
[0125] SEQ ID No.57:
[0126] DIQLTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPYTFGQGTKVEIK
[0127] SEQ ID No.58:
[0128] GACATCCAGTTGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCAGGGTATTAGCAGCTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCAACAGGCTAACAGTTTCCCGTACACTTTTGGCCAGGGGACCAAGGTGGAGATCAAA
[0129] SEQ ID No.59:
[0130] QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARDLRERRDGAMDVWGQGTTVTVSS
[0131] SEQ ID No.60:
[0132] CAGGTGCAGCTGGTACAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGGTGCGCCAGGCCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAAATATT CACAGAAGTTCCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGAGAGATCTTCGGGAACGGCGAGATGGGGCAATGGACGTCTGGGGCCAAGGGACCACGGTCACTGTCTCCTCA
[0133] The light chain variable region of antibody CX11 includes LCDR1, LCDR2, and LCDR3, with the LCDR1 sequence shown in SEQ ID No. 61, the LCDR2 sequence shown in SEQ ID No. 62, and the LCDR3 sequence shown in SEQ ID No. 63. It also includes frame region sequences outside the complementarity-determining regions. The heavy chain variable region includes HCDR1, HCDR2, and HCDR3, with the HCDR1 sequence shown in SEQ ID No. 64, the HCDR2 sequence shown in SEQ ID No. 65, and the HCDR3 sequence shown in SEQ ID No. 66. It also includes frame region sequences outside the complementarity-determining regions. The amino acid sequence of the light chain variable region of antibody CX11 is shown in SEQ ID No. 67; it can be obtained by translating and expressing the nucleotide sequence shown in SEQ ID No. 68, or by translating and expressing a similar codon-optimized nucleotide sequence. The amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 69; it can be obtained by translating and expressing the nucleotide sequence shown in SEQ ID No. 70, or by translating and expressing a similar codon-optimized nucleotide sequence.
[0134] SEQ ID No. 61: QSLLHSNGYNY
[0135] SEQ ID No. 62: LGS
[0136] SEQ ID No. 63: MQALQTPYT
[0137] SEQ ID No. 64: GFTFSNAW
[0138] SEQ ID No.65:IRSKTNGGTT
[0139] SEQ ID No.66:TTVAY
[0140] SEQ ID No.67:
[0141] DVVMTQTPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKVEIK
[0142] SEQ ID No.68:
[0143] GATGTTGTGATGACTCAGACTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCCGTACACTTTTGGCCAGGGGACCAAGGTGGAAATCAAA
[0144] SEQ ID No.69:
[0145] EVHLVESGGGLAKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIRSKTNGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYFCTTVAYWGQGTLVTVSS
[0146] SEQ ID No.70:
[0147] GAAGTGCATCTGGTGGAGTCTGGGGGAGGCTTGGCAAAGCCTGGGGGGTCCCTTAGACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAACGCCTGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTGGCCGTATTAGAAGCAAAACTAATGGT GGGACAACAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCAAAAAACACACTGTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTTCTGTACAACAGTGGCCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA
[0148] When preparing antibodies CX3, CX4, CX5, CX8, CX9, CX10, or CX11, an expression vector capable of expressing the amino acid sequence of each antibody can be pre-constructed, the constructed expression vector is transfected into a host cell, and after induction culture, the antibody CX3, CX4, CX5, CX8, CX9, CX10, or CX11 can be extracted and purified from the product of the engineered strain.
[0149] Furthermore, chimeric antigen receptor T cell anti-IL13Rα2 CAR-T cells were constructed using the scFv sequences of antibodies CX3, CX4, CX5, CX8, CX9, CX10, or CX11 as the core. First, a CAR structure containing the anti-IL13Rα2 antibody scFv sequence was designed, and an expression vector containing the CAR structure was constructed. After lentiviral packaging, T cells were infected, and after screening, anti-IL13Rα2 CAR-T cells were obtained and named CAR-T-CX3, CAR-T-CX4, CAR-T-CX5, CAR-T-CX8, CAR-T-CX9, CAR-T-CX10, and CAR-T-CX11, respectively.
[0150] The effects of anti-IL13Rα2 CAR-T cells on IL13Rα2-positive cells were investigated. The results showed that all CAR-T cells exhibited specific killing effects on IL13Rα2-positive model cells, such as highly efficient killing of U87 and U251 cells expressing IL13Rα2. Furthermore, the killing effect significantly increased with the increase in the proportion of CAR-T cells added. Anti-IL13Rα2 CAR-T cells had no killing effect on IL13Rα2-negative model cells, such as A549 cells. Different types of CAR-T cells showed varying killing effects on IL13Rα2-positive cells, with CAR-T-CX4 and CAR-T-CX10 showing the best killing effects. Based on these characteristics, anti-IL13Rα2 CAR-T cells can be used for the treatment of IL13Rα2-positive tumors.
[0151] Interleukin-13 receptor α2 (IL13Rα2) is a tumor-restricted transmembrane glycoprotein that is highly expressed on the surface of over 70% of glioblastoma and high-grade glioma cells, and its expression level is often correlated with tumor invasiveness and poor prognosis. In contrast, healthy brain tissue, glial cells, and neurons hardly express IL13Rα2, significantly reducing the risk of targeted therapy damaging normal central nervous system tissues, making it a highly promising and ideal target antigen for CAR-T immunotherapy in gliomas. Based on the specificity of anti-IL13Rα2 CAR-T cells, they are suitable for use in CAR-T cell therapy formulations for glioblastoma.
[0152] The present invention will now be described with reference to the accompanying drawings. Experimental methods not specifically described in terms of operation steps are performed in accordance with the corresponding product manuals. Unless otherwise specified, the instruments, reagents, and consumables used in the embodiments can be purchased from commercial companies.
[0153] Example 1: Screening and validation of anti-IL13Rα2 antibodies
[0154] Antibody sequences that identify IL13Rα2 were screened using a fully human phage display library.
[0155] With an initial OD value of approximately 0.1, inoculate an appropriate amount of the original phage library culture into a 500ml Erlenmeyer flask containing 2×YT medium, and add 100 μg / mL ampicillin and 2% glucose. Incubate at 250rpm and 37℃ for approximately 3 hours, until the OD600 value reaches approximately 0.5. Take approximately 3×10⁻⁶ cells / mL of the culture. 12M13KO7 helper phage was added to the above bacterial culture and incubated at 37°C for 30 minutes. The infected culture was then transferred to a 50ml centrifuge tube and centrifuged at 2400g, 12°C for 30 minutes, discarding the supernatant. The pellet was resuspended in 600ml of 2×YT medium, and ampicillin (100 μg / mL), kanamycin (60 μg / mL), and IPTG (100 μM) were added to a final concentration. The culture was incubated overnight at 30°C and 200 rpm. The next day, the culture was collected and centrifuged at 2400g, 12°C for 30 minutes. After centrifugation, 36ml of the supernatant was transferred to a new 50ml centrifuge tube, and 9ml of PEG / NaCl was added. The mixture was thoroughly mixed and incubated on ice for 1-2 hours. After 1-2 hours, the mixture was centrifuged at 4000 rpm, 4°C for 30 minutes. After centrifugation, gently discard the supernatant, resuspend the phage pellet in 3 ml of 1×PBS / 5% FBS solution, and store at 4°C for later use.
[0156] The purified phage antibody library was added to a pre-prepared IL13Rα2-His protein-coated 96-well plate and incubated at 4°C for 60 minutes. After incubation, the plate was washed with 5% FBS / PBS to remove as much supernatant as possible. This was repeated 10-30 times. The phage was eluted with 500 μl of 0.1 M, pH 2.2 Glycine and incubated at room temperature for 10 minutes. After centrifugation, the supernatant was transferred to a new tube, and 50 μl of pH 9.5 Tris-HCl was added to neutralize the pH. The eluted phage was then transferred to a new 15 ml centrifuge tube for TG1 infection.
[0157] The above process was repeated twice. The resulting clones were then subjected to Phage ELISA testing. The results showed that many ELISA-positive clones were obtained. Clones with OD read values greater than 0.7 were selected and named CX3, CX4, CX5, CX8, CX9, CX10, and CX11, respectively. Sanger sequencing was performed on each of the seven clones to obtain the scFv sequence.
[0158] Example 2: Construction of CAR-T cells containing anti-IL13Rα2 antibody
[0159] Based on the scFvs of the seven anti-IL13Rα2 antibodies screened in Example 1, CAR structures were constructed respectively, as shown in the figure. Figure 1 As shown.
[0160] Seven candidate IL13Rα2 antibody sequences (CX3, CX4, CX5, CX8, CX9, CX10, CX11) were cloned into a CAR expression lentiviral vector. The vector included structures such as... Figure 1The CAR structure is shown. Using the clinically common E13Y (US7514537B2) as a control, a lentiviral vector containing the corresponding CAR structure was constructed using the same method. After plasmid extraction, lentiviral packaging, concentration, and viral titer determination, the lentiviral vector was cryopreserved at -80°C for later use. On day 1, T cells were activated with anti-CD3 / CD28 Dynabeads, and the cell density was adjusted to 1e6 / ml. On day 2, the corresponding volume of lentiviral vector was added to T cells at MOI=2 for infection. On day 5, anti-CD3 / CD28 Dynabeads were removed, and cell counting, passage, and fluid replacement were performed. On day 9, 3×10⁶ cells were collected. 5 T cells were stained with IL13Rα2-Fc protein and anti-Fc fluorescently labeled antibody, and the CAR positivity rate was detected by flow cytometry. The results are as follows: Figure 2 As shown. CAR-T cells are cultured continuously for about 11 days, then harvested for direct use in functional experiments or cryopreserved for later use.
[0161] Example 3: Verification of the killing effect of anti-IL13Rα2 CAR-T cells
[0162] The cytotoxic effects of the prepared anti-IL13Rα2 CAR-T cells on different cell types were investigated. Human glioma cell lines U87 (IL13Rα2 positive cells), U251 (IL13Rα2 positive cells), and A549 (IL13Rα2 negative cells) were used as cell models to examine the effects of CAR-T cells. Cell models were cultured in RPMI-1640 or DMEM medium containing 10% fetal bovine serum and 1% penicillin-dextrose antibody, and passaged approximately every 2-3 days.
[0163] The IL13Rα2-positive tumor cell line U87 was injected with 1.5 × 10⁻⁶ cells / mL. 4 Cells were seeded at a density of 100 cells / well in flat-bottomed 96-well plates and cultured overnight. The next day, different types of CAR-T cells were added at E:T ratios of 3:1, 1:1, and 0.3:1. After 24 hours of co-culture, LDH release was measured, and CAR-T cell cytotoxicity to target cells was calculated. Results are as follows: Figure 3 As shown, CAR-T cells containing different anti-IL13Rα2 antibodies all exhibited killing effects on the U87 human glioma cell line, which was positive for IL13Rα2. Furthermore, the killing effect on the U87 human glioma cell line was enhanced with the increase in the proportion of CAR-T cells added. In addition, the killing abilities of different types of anti-IL13Rα2 antibodies varied, but all were higher than those of E13Y, which is commonly used in clinical practice. This indicates that CAR-T cells prepared from the seven anti-IL13Rα2 antibodies obtained in this invention have better killing ability against tumor cells.
[0164] To investigate whether CAR-T cells only have a killing effect on the U87 cell line, another IL13Rα2-positive cell line, U251 cells, was used to verify the effect of CAR-T cells. U251 cells were cultured at 1.5 × 10⁻⁶ cells per cell line. 4 Cells were seeded at a density of 10 cells / well in flat-bottomed 96-well plates and cultured overnight. The next day, CAR-T cells were added at E:T ratios of 3:1, 1:1, and 0.3:1. After 24 hours of co-culture, LDH release was measured, and CAR-T cell cytotoxicity to target cells was calculated. Results are as follows: Figure 4 As shown, each CAR-T cell also has a significant killing effect on another type of IL13Rα2 positive cell, U251, and the killing effect can be enhanced with the increase of the proportion of CAR-T cells added.
[0165] In addition, the effect of CAR-T cells on IL13Rα2-negative cells A549 was investigated. The IL13Rα2-negative cell line A549 was cultured at 1.5 × 10⁻⁶ cells / year. 4 Cells were seeded at a density of 10 cells / well in flat-bottomed 96-well plates and cultured overnight. The next day, CAR-T cells were added at E:T ratios of 3:1, 1:1, and 0.3:1. After 24 hours of co-culture, LDH release was measured, and CAR-T cell cytotoxicity to target cells was calculated. Results are as follows: Figure 5 As shown, none of the seven anti-IL13Rα2 CAR-T cells had a significant killing effect on A549 cells, indicating that the killing effect of CAR-T cells is specific, with a significant killing effect on IL13Rα2 positive cells, but no effect on IL13Rα2 negative cells.
[0166] Further analysis was conducted on the expression of IL2 and IFN-γ when CAR-T cells acted on target cells. For the co-incubation products of different CAR-T cells with U87 cells or U251 cells, cell supernatants were collected, and the contents of IL2 and IFN-γ in the supernatants were measured. Results are as follows: Figure 6 and Figure 7 As shown, ELISA results indicate that various CAR-T cells have varying degrees of killing effects, with CX4 and CX10 CAR-T cells exhibiting stronger killing effects.
[0167] The embodiments of the present invention have been described in detail above, but the content described is only a preferred embodiment of the present invention and should not be considered as limiting the scope of the present invention. All equivalent changes and improvements made within the scope of the present invention should still fall within the patent coverage of the present invention.
Claims
1. An anti-IL13Rα2 antibody, characterized in that: The antibodies were named CX3, CX4, CX5, CX8, CX9, CX10, or CX11. The variable region of the antibody CX3 light chain includes LCDR1 as shown in SEQ ID No. 1, LCDR2 as shown in SEQ ID No. 2, and LCDR3 as shown in SEQ ID No. 3; the variable region of the heavy chain includes HCDR1 as shown in SEQ ID No. 4, HCDR2 as shown in SEQ ID No. 5, and HCDR3 as shown in SEQ ID No.
6. The variable region of the antibody CX4 light chain includes LCDR1 as shown in SEQ ID No. 11, LCDR2 as shown in SEQ ID No. 12, and LCDR3 as shown in SEQ ID No. 13; the variable region of the heavy chain includes HCDR1 as shown in SEQ ID No. 14, HCDR2 as shown in SEQ ID No. 15, and HCDR3 as shown in SEQ ID No.
16. The variable region of the antibody CX5 light chain includes LCDR1 as shown in SEQ ID No. 21, LCDR2 as shown in SEQ ID No. 22, and LCDR3 as shown in SEQ ID No. 23; the variable region of the heavy chain includes HCDR1 as shown in SEQ ID No. 24, HCDR2 as shown in SEQ ID No. 25, and HCDR3 as shown in SEQ ID No.
26. The variable region of the antibody CX8 light chain includes LCDR1 as shown in SEQ ID No. 31, LCDR2 as shown in SEQ ID No. 32, and LCDR3 as shown in SEQ ID No. 33; the variable region of the heavy chain includes HCDR1 as shown in SEQ ID No. 34, HCDR2 as shown in SEQ ID No. 35, and HCDR3 as shown in SEQ ID No.
36. The variable region of the antibody CX9 light chain includes LCDR1 as shown in SEQ ID No. 41, LCDR2 as shown in SEQ ID No. 42, and LCDR3 as shown in SEQ ID No. 43; the variable region of the heavy chain includes HCDR1 as shown in SEQ ID No. 44, HCDR2 as shown in SEQ ID No. 45, and HCDR3 as shown in SEQ ID No.
46. The variable region of the light chain of antibody CX10 includes LCDR1 as shown in SEQ ID No. 51, LCDR2 as shown in SEQ ID No. 52, and LCDR3 as shown in SEQ ID No. 53; the variable region of the heavy chain includes HCDR1 as shown in SEQ ID No. 54, HCDR2 as shown in SEQ ID No. 55, and HCDR3 as shown in SEQ ID No.
56. The variable region of the light chain of antibody CX11 includes LCDR1 with the sequence shown in SEQ ID No. 61, LCDR2 with the sequence shown in SEQ ID No. 62, and LCDR3 with the sequence shown in SEQ ID No. 63; the variable region of the heavy chain includes HCDR1 with the sequence shown in SEQ ID No. 64, HCDR2 with the sequence shown in SEQ ID No. 65, and HCDR3 with the sequence shown in SEQ ID No.
66.
2. The anti-IL13Rα2 antibody according to claim 1, characterized in that: The amino acid sequence of the light chain variable region of antibody CX3 is shown in SEQ ID No. 7, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No. 9; The amino acid sequence of the light chain variable region of antibody CX4 is shown in SEQ ID No. 17, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No.
19. The amino acid sequence of the light chain variable region of antibody CX5 is shown in SEQ ID No. 27, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No.
29. The amino acid sequence of the light chain variable region of antibody CX8 is shown in SEQ ID No. 37, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No.
39. The amino acid sequence of the light chain variable region of antibody CX9 is shown in SEQ ID No. 47, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No.
49. The amino acid sequence of the light chain variable region of antibody CX10 is shown in SEQ ID No. 57, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No.
59. The amino acid sequence of the light chain variable region of antibody CX11 is shown in SEQ ID No. 67, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID No.
69.
3. The anti-IL13Rα2 antibody according to claim 2, characterized in that: The nucleotide sequence encoding the variable region of the light chain of antibody CX3 is shown in SEQ ID No. 8, and the nucleotide sequence encoding the variable region of the heavy chain is shown in SEQ ID No.
10. The nucleotide sequence encoding the light chain variable region of antibody CX4 is shown in SEQ ID No. 18, and the nucleotide sequence encoding the heavy chain variable region is shown in SEQ ID No.
20. The nucleotide sequence encoding the light chain variable region of antibody CX5 is shown in SEQ ID No. 28, and the nucleotide sequence encoding the heavy chain variable region is shown in SEQ ID No.
30. The nucleotide sequence encoding the variable region of the light chain of antibody CX8 is shown in SEQ ID No. 38, and the nucleotide sequence encoding the variable region of the heavy chain is shown in SEQ ID No.
40. The nucleotide sequence encoding the light chain variable region of antibody CX9 is shown in SEQ ID No. 48, and the nucleotide sequence encoding the heavy chain variable region is shown in SEQ ID No.
50. The nucleotide sequence encoding the light chain variable region of antibody CX10 is shown in SEQ ID No. 58, and the nucleotide sequence encoding the heavy chain variable region is shown in SEQ ID No.
60. The nucleotide sequence encoding the light chain variable region of antibody CX11 is shown in SEQ ID No. 68, and the nucleotide sequence encoding the heavy chain variable region is shown in SEQ ID No.
70.
4. A chimeric antigen receptor T cell, characterized in that: The expression vectors comprising the scFv sequence of any of the anti-IL13Rα2 antibodies according to claims 1-3 are named CAR-T-CX3, CAR-T-CX4, CAR-T-CX5, CAR-T-CX8, CAR-T-CX9, CAR-T-CX10 or CAR-T-CX11.
5. The chimeric antigen receptor T cell according to claim 4, characterized in that: The expression vector includes the scFv sequence of antibody CX4 or CX10.
6. The use of the chimeric antigen receptor T cells as described in claim 4 or 5 in the preparation of antitumor drugs.
7. The application according to claim 6, characterized in that: Used for IL13Rα2-positive tumor cells.
8. The application according to claim 7, characterized in that: Drugs used for glioblastoma.
Citation Information
Patent Citations
Chimeric immunoreceptor useful in treating human gliomas
US7514537B2
